Quarantine authorities “Celltrion Rekirona is supplied from mid-February…administered to people over 60”

Input 2021.02.06 14:50

The quarantine authorities announced on the 6th that it will supply Celltrion Reckirona, a treatment for Celltrion’s novel coronavirus infection (Corona 19), conditionally approved by the Ministry of Food and Drug Safety, to medical institutions from mid-February.

Lee Sang-won, head of the epidemiological investigation and analysis of the central quarantine countermeasures headquarters, said at a briefing on the day, “The range of subjects to be administered (Reckirona) will be finalized after expert review according to the effects approved by the Ministry of Food and Drug Safety.” For smooth supply and demand, medical institutions will consult directly from pharmaceutical companies.”

Director Lee said, “(Rekironaju) is known to improve clinical symptoms in patients over 60 years of age or mild patients with underlying diseases,” he said. “The supply of this treatment can play a role in alleviating the pain of patients. I am eagerly hoping to be there.

Rekironaju is the first approved drug for COVID-19 in Korea. Based on the results of the final inspection committee meeting the day before, the Ministry of Food and Drug Safety decided to grant conditional product approval for Rekkirona. However, he said that the administration target is limited to patients with mild or moderate symptoms in the high-risk group.

The high-risk group identified by the Ministry of Food and Drug Safety refers to patients over the age of 60 or with at least one of cardiovascular disease, chronic respiratory disease, diabetes, and high blood pressure. According to the approved usage and dosage, Rekironaju should be injected intravenously for 90 minutes (±15 minutes) of 40 mg/kg of adult body weight.